MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
44.85
+0.15
+0.34%
After Hours: 44.88 +0.03 +0.07% 19:58 04/26 EDT
OPEN
44.68
PREV CLOSE
44.70
HIGH
45.37
LOW
44.34
VOLUME
21.28M
TURNOVER
0
52 WEEK HIGH
70.94
52 WEEK LOW
44.34
MARKET CAP
90.90B
P/E (TTM)
11.61
1D
5D
1M
3M
1Y
5Y
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
LKQ Corporation stock tumbled 12.3% after the company reported a Q1 earnings miss and cut its FY24 outlook. Textron Inc. Shares plunged 9.5% after it reported worse-than-expected Q1 financial results. The ten large-cap stocks were the worst performers last week.
Benzinga · 2h ago
Amgen’s Blincyto data send Cullinan higher
Cullinan Therapeutics added ~58% last week after peer-reviewed data for Amgen's leukemia therapy, Blincyto. The drug targets CD19 surface antigens on B cells similar to CGEM's lymphoma candidate. The company's stock rose 31% on Friday after Nature Medicine published the data.
Seeking Alpha · 1d ago
Dividend Champion, Contender, And Challenger Highlights: Week Of April 28
The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts. In the past week, the following companies declared dividends which changed from their previous payouts: Ameriprise Financial and The Southern Company. Justin Law provides a weekly summary of dividend activity for D dividend Champions, Contenders, and Challengers.
Seeking Alpha · 1d ago
2 Very Cheap Turnarounds Yielding Up To 7%
AT&T and Bristol-Myers Squibb are two beaten-down stocks with attractive dividend yields. AT&T has solid operating fundamentals and a low valuation, while Bristol- myers has a strong pipeline and is undervalued. Both stocks offer potential for high income and capital appreciation if their valuations reset.
Seeking Alpha · 1d ago
Wall Street Breakfast: What Moved Markets
The S&P 500 scored its best weekly performance since October 2023 this week. The tech-heavy Nasdaq Composite rose +4.2% and the Dow rose +0.7%. Tesla, Microsoft, and Alphabet reported good quarterly results. Inflation data pointed to stalling growth and sticky inflation.
Seeking Alpha · 1d ago
UPDATE 1-S&P 500 Q1 earnings estimated growth improves; stocks up for week
S&P 500 year-over-year earnings growth for the first quarter of 2024 is seen at 5.6%, up from 4.3% last week. About 78% of first-quarter estimated earnings for S&p 500 companies are beating expectations. Stocks are up more than 2% for the week but are still down 2% since March.
Reuters · 2d ago
Bristol, Sanofi, Takeda gain positive CHMP recommendations
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions for treatments from Bristol-Myers Squibb, Sanofi, and Takeda. Bristol's Opdivo is endorsed for approval as a first-line treatment for urothelial cancer.
Seeking Alpha · 2d ago
Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital
Dow Jones · 2d ago
More
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.